Background & Aims Long-term outcomes in portopulmonary hypertension (PoPH) are poorly
studied in the current era of pulmonary hypertension management. We analysed the effect …

The prognostic importance of follow-up haemodynamics and the validity of multidimensional
risk assessment are not well established for systemic sclerosis (SSc)-associated pulmonary …

Rationale: Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is
a rare and largely unknown complication of NF1. Objectives: To describe characteristics and …

Background To date, nothing is known about the evolution of survival in systemic sclerosis-associated
pulmonary arterial hypertension (PAH) over the last decade. Methods This study …

There is no data on initial dual oral combination therapy in patients with inoperable CTEPH.
The aim of our study was to evaluate the efficacy and safety of different regimen of dual …

Pulmonary hypertension (PH) is a significant and well-recognised complication of
sarcoidosis that markedly increases mortality. The current European Society of Cardiology (ESC)/…

Introduction: hypertension (CTEPH). PEA is however not feasible in about one third of
patients with CTEPH, mainly due to the presence of distal lesions and pulmonary vascular …

… Delphine Bourlier …

BACKGROUND: To enhance compliance with national nutrition recommendations in breast
cancer survivors (BCS), a 3-year program granted by the Regional Health Authority began in …

Introduction: Pulmonary hypertension associated with neurofibromatosis type 1 (PH-NF1) is
a rare but severe complication of NF1. The largest study about PH-NF1 described 8 patients …